ReFrame | Jotup

How a new drug prototype regenerates lung tissue

Retrieved on:

Wednesday, April 10, 2024

LA JOLLA, Calif., April 10, 2024 /PRNewswire/ -- Pulmonary diseases are a leading cause of morbidity and mortality worldwide. For many progressive lung diseases like idiopathic pulmonary fibrosis (IPF), a key issue is a low supply of new stem cells to repair and reverse damage. These cells are responsible for regenerating and increasing the growth of healthy tissue—without them, lung function decreases and a range of severe illnesses can take hold.

Key Points:

"We chose the lung because the stem cell population of the lower airway doesn't regenerate as effectively as one ages."
However, there currently are no available treatment options that regenerate damaged lung tissue.
To see whether existing drug mechanisms could increase growth of lung stem cells, the team turned to ReFRAME , a drug repurposing library built by Calibr-Skaggs.
While NZ-97 is a prototype drug, it's chemically similar to CMR316, Calibr-Skagg's drug that will be entering a phase 1 clinical trial in a few months.

ReFrame and IMDbPro Award the ReFrame Stamp for Gender-Balanced Hiring to 94 of the 200 Most Popular TV and Streaming Series of 2022-23, including Emmy Nominees Abbott Elementary, The Bear, Yellowjackets, and Wednesday

Retrieved on:

Wednesday, August 16, 2023

The 94 awardees represent 47% of the 200 most popular scripted series, which is equivalent to the 2021-22 season results.

Key Points:

The 94 awardees represent 47% of the 200 most popular scripted series, which is equivalent to the 2021-22 season results.
For the second consecutive year, the majority of Emmy Nominees for Outstanding Comedy Series received the Stamp.
IMDbPro rankings are based on the actual page views of the more than 200 million monthly visitors to IMDb worldwide.
ReFrame encourages all scripted productions to implement equitable hiring practices and apply to earn the ReFrame Stamp year-round.

Sutro Biopharma and Blackstone Announce Royalty Financing Collaboration

Retrieved on:

Monday, June 26, 2023

Partnership, Streptococcus, Senior, BX, TD, ReFrame, Platinum, Sutro, Blackstone, Patient, SAN, Peterborough, STRO, PCV, Spacecraft, Ovarian cancer, NYSE, ROR1, Fine chemical

SOUTH SAN FRANCISCO, Calif and NEW YORK, June 26, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), and Blackstone (NYSE: BX), today announced the companies have entered into a royalty financing collaboration agreement where funds managed by Blackstone Life Sciences will provide $140 million upfront, with up to an additional $250 million in future milestone payments triggered at various return thresholds, in exchange for Sutro’s 4% royalty, or revenue interest, in the potential future sales of Vaxcyte’s products, including VAX-24 and other products that Vaxcyte develops under its license with Sutro.

Key Points:

- Sutro will receive $140 million upfront and is eligible to receive up to an additional $250 million in future milestone payments in exchange for the royalty, or revenue interest, in potential future sales of Vaxcyte’s products -
SOUTH SAN FRANCISCO, Calif and NEW YORK, June 26, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), and Blackstone (NYSE: BX), today announced the companies have entered into a royalty financing collaboration agreement where funds managed by Blackstone Life Sciences will provide $140 million upfront, with up to an additional $250 million in future milestone payments triggered at various return thresholds, in exchange for Sutro’s 4% royalty, or revenue interest, in the potential future sales of Vaxcyte’s products, including VAX-24 and other products that Vaxcyte develops under its license with Sutro.
Vaxcyte’s lead candidate, VAX-24, is a Phase 3 ready, 24-valent next-generation pneumococcal conjugate vaccine (PCV) with enhanced serotype coverage and immunogenicity.
Vaxcyte’s PCV franchise is enabled by Sutro’s XpressCF® cell-free protein synthesis technology.
“We established an important and valued partnership with Blackstone Life Sciences through this transaction, while continuing to capitalize on the value generated from the technologies underlying our cell-free protein synthesis and conjugation platforms,” said Bill Newell, Sutro’s Chief Executive Officer.

ReFrame Solutions Appoints P. Kelly Farr Jr. as Chief Strategy Officer to Drive Innovation and Growth

Retrieved on:

Wednesday, June 7, 2023

Public sector, Lucent, Growth, SAS Institute, ReFrame, Ministry of Finance, Economic Stabilization and National Policies, Augusta University, Strategic planning, Pakistan Software Export Board, CSO, Management

In this role, Kelly will be responsible for developing and executing strategic initiatives that drive innovation, growth, and customer excellence across the organization.

Key Points:

In this role, Kelly will be responsible for developing and executing strategic initiatives that drive innovation, growth, and customer excellence across the organization.
"We are thrilled to welcome Kelly to the executive team as our new Chief Strategy Officer," said Scott Schooley, Chairman of the Board.
"I am honored to join ReFrame Solutions as Chief Strategy Officer," said Kelly Farr "I believe that ReFrame has tremendous potential for further growth and innovation, and I am excited to work alongside a talented team to shape the company's strategic direction.
His proven ability to drive strategic vision, combined with his passion for innovation, makes him an invaluable addition to the ReFrame Solutions leadership team.

Sutro Biopharma Announces Oral Presentation at ASCO 2023 Featuring Data for Luveltamab Tazevibulin from the Phase 1 Dose-Expansion Study in Ovarian Cancer and the Initiation of the Phase 2/3 Pivotal Study REFRaME-O1

Retrieved on:

Saturday, June 3, 2023

SOUTH SAN FRANCISCO, Calif., June 03, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that results from a Phase 1 dose-expansion study of luveltamab tazevibulin (luvelta), a novel Folate receptor alpha (FolRα)-targeting ADC, in patients with advanced ovarian cancer were featured in an oral presentation at the 2023 American Society of Clinical Oncology (ASCO 2023) Annual Meeting in Chicago, IL. In parallel, the Company continues to advance the clinical development of luvelta and announced that sites are now open for enrollment in REFRaME-O1, the pivotal Phase 2/3 study for patients with platinum-resistant ovarian cancer.

Key Points:

In parallel, the Company continues to advance the clinical development of luvelta and announced that sites are now open for enrollment in REFRaME-O1, the pivotal Phase 2/3 study for patients with platinum-resistant ovarian cancer.
Responses were seen in FolRα expressing patients with TPS >25%, addressing patients who may not be eligible for other approved therapies targeting FolRα.
“On the heels of these positive results, we are thrilled that REFRaME, our pivotal Phase 2/3 trial, is officially underway.
From the clinical and nonclinical data gathered, we maintain our positive outlook that luvelta could potentially serve multiple additional indications where patients express FolRα.”

Sutro Biopharma Announces the Departure of President of Research & Chief Scientific Officer

Retrieved on:

Thursday, April 27, 2023

ReFrame, SAN, STRO, ADC, Spacecraft, Coronavirus Scientific Advisory Board, Synthetic biology, ROR1, Pharmaceutical industry, Management

“On behalf of Sutro, we would like to thank Trevor for his twelve years of scientific leadership and contributions to our innovative science—most recently as President of Research & Chief Scientific Officer and as a member of our senior management team,” said Bill Newell, Sutro’s Chief Executive Officer.

Key Points:

“On behalf of Sutro, we would like to thank Trevor for his twelve years of scientific leadership and contributions to our innovative science—most recently as President of Research & Chief Scientific Officer and as a member of our senior management team,” said Bill Newell, Sutro’s Chief Executive Officer.
“Trevor’s scientific vision and commitment enabled the six product candidates currently in the clinic that were discovered, developed and manufactured with our cell-free technology.
I am confident that the Sutro team will continue to execute and drive value, and I look forward to contributing to Sutro’s success through participating on its Scientific Advisory Board.”
Dr. Hallam will transition on May 31, 2023 from the role of President of Research & Chief Scientific Officer to his membership on Sutro’s Scientific Advisory Board.
Nicki Vasquez, Ph.D., Chief Portfolio Strategy & Alliance Officer, who is currently a member of the Sutro Senior Management Team, will assume interim responsibility for leading the research organization.

Sutro Biopharma Reports Full Year 2022 Financial Results, Business Highlights and Select Anticipated Milestones

Retrieved on:

Thursday, March 30, 2023

SOUTH SAN FRANCISCO, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial results for the full year 2022, its recent business highlights, and a preview of select anticipated milestones.

Key Points:

The safety profile is generally consistent with prior data; asymptomatic neutropenia was the primary adverse event and no new safety signals were observed.
Additional Pipeline Programs: A Sutro Research Forum, held in 2022, highlighted STRO-003 and Sutro’s emerging research portfolio.
Sutro bolstered the Senior Management Team with the promotion of Brunilda Shtylla to Chief Business Officer, who leads Business Development.
Total operating expenses for the year ended December 31, 2022 were $196.7 million, as compared to $160.4 million for the same period in 2021.

Reframe Named to Fast Company's List of the World's Most Innovative Companies for 2023

Retrieved on:

Thursday, March 2, 2023

Macdonald, NASA, Stripe, Spotify, Early stage innovation company, OpenAI, Neuroscience, Organizational founder, Organization, Editorial, MrBeast, Drinking, Stanford University, Harvard University, University, Management, Airbnb, Chipotle, ReFrame

"We're so honored to make the list this year for most innovative companies and we continue to be motivated by the impact we've had so far on so many lives. It truly inspires us to see so many people in our community making positive changes and supporting others on the journey." --Vedant Pradeep, Cofounder & CEO of Reframe.

Key Points:

ATLANTA, March 2, 2023 /PRNewswire-PRWeb/ -- Reframe has been named to Fast Company's prestigious annual list of the https://www.fastcompany.com/most-innovative-companies/list for 2023.
In addition to the World's 50 Most Innovative Companies, 540 organizations are recognized across 54 sectors and regions.
The World's Most Innovative Companies is Fast Company's signature franchise and one of its most highly anticipated editorial efforts of the year.
Fast Company's Most Innovative Companies issue (March/April 2023) is available online here and on newsstands beginning March 14.

IMDb Brings Coverage of the Sundance Film Festival Experience to Entertainment Fans Across the Globe

Retrieved on:

Tuesday, January 17, 2023

Hosted on the first night of the Sundance Film Festival, the event will celebrate the Sundance Institute and artists changing the face of independent cinema.

Key Points:

Hosted on the first night of the Sundance Film Festival, the event will celebrate the Sundance Institute and artists changing the face of independent cinema.
“A Taste of Sundance” will raise crucial funds for the essential work Sundance Institute does year-round, including grants, mentorships, critical resources, and hosting the festival.
Coverage will be featured on the IMDb site, apps, and social channels, reaching hundreds of millions of entertainment fans around the world.
Previous IMDb STARmeter Award recipients at the Sundance Film Festival include Rachel Brosnahan, Nicholas Braun, Mindy Kaling, Bill Skarsgård, and Peter Dinklage.

IMDb Announces Significant Policy and Product Updates That Empower Entertainment Professionals to Showcase Themselves to Entertainment Industry Decision-Makers

Retrieved on:

Tuesday, December 13, 2022

These product and policy updates are part of an ongoing commitment from IMDb to support progress towards more equitable hiring in the entertainment industry, and align with the IMDb mission to be the most accurate and complete source of entertainment information.

Key Points:

These product and policy updates are part of an ongoing commitment from IMDb to support progress towards more equitable hiring in the entertainment industry, and align with the IMDb mission to be the most accurate and complete source of entertainment information.
View the full release here: https://www.businesswire.com/news/home/20221212005826/en/
IMDb announces significant product and policy updates.
IMDbPro, a membership service for entertainment industry professionals, empowers customers with information and features designed to help them achieve success throughout all stages of their career.
For entertainment industry professionals, IMDb provides IMDbPro and Box Office Mojo .